山东未名生物医药股份有限公司 2024年度独立董事述职报告（刘洋） 2024年度，公司股东大会和董事会的召集和召开程序符合《公司法》等法律法规和 《公司章程》的规定，所作决议合法有效。本人对2024年度本人出席的董事会审议的议 案均投了赞成票，未提出有异议的事项。 （二）参与董事会专门委员会工作情况 本人作为山东未名生物医药股份有限公司（以下简称"公司"）的第五届董事会的 独立董事，2024年度，本人严格遵照《公司法》、《上市公司治理准则》、《上市公司 独立董事管理办法》等法律、法规及《公司章程》等相关规定，认真履行独立董事职责， 出席董事会和股东大会会议，依托专业知识为公司经营决策和规范运作提出意见和建议， 并对公司相关事项发表了独立意见，切实维护公司和全体股东的利益。现将本人2024年 度履职情况述职如下： 一、独立董事的基本情况 本人刘洋，男，42岁，中国国籍，北京大学法律学士学位，现任职于淄博市张店区 国有资产运营有限公司，担任党总支委员、副总经理，兼任山东坤宏矿业有限公司董事 长，山东民祥化工科技有限公司党支部书记、监事长，淄博弘禄土地发展有限公司监事。 作为公司的独立董事，本人均拥有专业资质及能力 ...

作为公司独立董事，本人及直系亲属、主要社会关系均未直接或间接持有公司股份， 不在直接或间接持有公司已发行股份5%或5%以上的股东单位任职，没有从公司及其主要 股东或有利害关系的机构和人员处取得额外的、未予披露的其他利益，具备法律法规所 要求的独立性，不存在影响独立性的情况。 山东未名生物医药股份有限公司 2024年度独立董事述职报告（肖杰-离任） 作为山东未名生物医药股份有限公司（以下简称"公司"）的独立董事，2024年度 本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》等法律法规和《公 司章程》的规定，恪尽职守、勤勉尽责、忠实履行职责，积极出席相关会议，充分发挥 作为独立董事的独立作用，维护了公司整体利益和中小股东的合法权益。 本人于2022年8月22日任公司独立董事，并于2024年12月18日离任，现就2024年度 主要工作情况报告如下： 一、独立董事的基本情况 本人肖杰，男，55岁，中国国籍，硕士学历，现任深圳市永鹏会计师事务所（普通 合伙）公司执行事务合伙人职务，兼任深圳市股权投资研究会监事。本人因个人原因辞 去公司第五届董事会独立董事及董事会专门委员会相关职务。2024年12月18日，公 ...

山东未名生物医药股份有限公司 2024年度独立董事述职报告（张荣富） 本人作为山东未名生物医药股份有限公司（以下简称"公司"）第五届董事会独立 董事，任职期间本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》《上 市公司治理准则》《公司章程》及《公司独立董事制度》等法律法规、规范性文件的相 关规定和要求，忠实履行独立董事职责，认真审议董事会各项议案，为公司经营决策和 规范运作提出意见和建议，有效促进了公司的规范运作，切实维护公司和股东的合法权 益。现就本人2024年度任期内履行独立董事职责情况报告如下: 一、独立董事的基本情况 本人张荣富，1965年出生，中国国籍，本科学历，现任职于国浩律师（深圳）事务 所，担任合伙人职务。曾任铁道部建工局秘书、深圳市格威律师事务所律师、广东中意 达律师事务所合伙人和上海市建纬律师事务所深圳分所合伙人。现任公司独立董事。 截至目前，本人未持有公司股份，与其他持有公司5%以上股份的股东、董事、监事、 高级管理人员不存在关联关系，未受过中国证监会及其他有关部门的处罚和证券交易所 惩戒，未曾被中国证监会在证券期货市场违法失信信息公开查询平台公示或者被人民法 院纳入失信被执 ...

董 事 会 2025 年 4 月 23 日 根据公司独立董事蔡艳红女士、张荣富先生、刘洋先生、夏阳先生、肖杰先 生（已离任）的自查及其在公司的履职情况，公司董事会认为上述人员未在公司 担任除独立董事以外的任何职务，也未在公司主要股东单位担任任何职务，与公 司以及主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关 系，不存在其他影响独立董事独立性的情况。公司独立董事符合《上市公司独立 董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司 规范运作》中对独立董事独立性的相关要求。 山东未名生物医药股份有限公司 山东未名生物医药股份有限公司 关于独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引 第 1 号—主板上市公司规范运作》等要求，结合独立董事出具的《独立董事关于 独立性自查情况的报告》，山东未名生物医药股份有限公司（以下简称"公司"） 董事会就公司在任独立董事蔡艳红女士、张荣富先生、刘洋先生、夏阳先生、肖 杰先生（已离任）的独立性情况进行评估并出具如下专项意见： ...

山东未名生物医药股份有限公司 2024年度独立董事述职报告（蔡艳红） 本人作为山东未名生物医药股份有限公司（以下简称"公司"）第五届董事会的独 立董事，在任职期间严格按照《公司法》《证券法》《深圳证券交易所上市公司自律监 管指引第1号—主板上市公司规范运作》等相关法律法规、规范性文件及《公司章程》 《上市公司独立董事管理办法》《独立董事工作细则》等有关规定，本着独立、客观、 公正的原则，以恪尽职守、勤勉尽责的工作态度，积极出席相关会议，认真审议董事会 的各项议案，切实维护了公司和全体股东尤其是中小股东的利益。现将本人2024年度履 行独立董事职责情况汇报如下： 2024年度，本人积极参加公司董事会、股东大会，本着勤勉尽责的态度，积极关注 公司管理层对董事会决议的落实情况，认真审阅会议议案及相关材料，积极参与各项议 案的讨论，充分运用自身专业知识与实践经验，提出合理化意见和建议，为董事会的科 学、高效决策及股东大会的规范运作，发挥积极作用。本人对董事会审议的所有议案均 表示同意，无提出异议的事项，也无反对、弃权的情形。 报告期内，本人出席公司董事会、股东大会的具体情况如下： | | | | 独立董 | 任职期间 ...

山东未名生物医药股份有限公司 激励基金管理办法 (2025年4月21日第五届董事会第三十五次会议制定) 第一章 总则 第一条 为充分调动和发挥山东未名生物医药股份有限公司（以下简称"公 司"）员工的积极性、主动性和创造性，提升公司核心竞争能力，从而为股东带 来更高效、更持久的回报。根据《中华人民共和国公司法》《中华人民共和国证 券法》等有关法律法规及《公司章程》的规定，结合公司实际情况，设立公司激 励基金，并制定本管理办法。 第二条 本管理办法遵循的原则： 第四条 公司激励基金（以下简称"激励基金"）的实施对象为公司（包括 全资或控股子公司）在职员工： （一）公司董事（不含独立董事）、高级管理人员； （二）公司认为应当予以激励的中层管理人员、核心技术（业务）骨干； （三）公司董事会认为应当激励的其他员工。 根据公司发展战略及人才发展情况，由公司人力资源部拟定激励对象名单， 报公司董事会薪酬与考核委员会审核通过后提交公司董事会审定。 （一）坚持奖励和约束相结合； （二）坚持股东利益、公司利益和奖励对象的个人利益相结合； （三）符合法律、法规、规范性文件和《公司章程》的相关规定。 第三条 本管理办法是公司现有薪酬 ...

作为山东未名生物医药股份有限公司（以下简称"公司"）的独立董事，本人严格 按照《公司法》《上市公司独立董事管理办法》《上市公司治理准则》《公司章程》等 相关法律法规和规章制度的规定和要求，诚信、勤勉、独立地履行独立董事职责，积极 出席相关会议，认真审议各项议案，促进公司规范运作，切实维护全体股东尤其是中小 股东的合法权益。现将2024年度履职情况报告如下： 山东未名生物医药股份有限公司 2024年度独立董事述职报告（夏阳） 本人夏阳，男，61岁，中国国籍，现任于北京华达杰瑞生物技术有限公司董事长职 务，曾任于天津药物研究院，深圳海王药业有限公司经理，武汉人福科技股份有限公司 医药公司总经理，北京紫华康泰医药公司（现更名为北京博智创盛医药有限公司）副总 裁、总经理，Frost & Sullivan中国区医药副总裁。2022年8月至今任公司独立董事。 本人作为公司的独立董事，符合《上市公司独立董事管理办法》规定的独立性要 求和任职条件，没有在公司担任除独立董事以外的其他任何职务，没有从公司及其主 要股东或有利害关系的机构和人员处取得额外的、未予披露的其他利益，不存在影响 上市公司独立性和独立董事独立性的情况。 一 ...

Financial Performance - The company's operating revenue for 2024 was ¥360,405,014.10, a decrease of 16.14% compared to ¥429,790,105.06 in 2023[19]. - The net loss attributable to shareholders for 2024 was ¥137,313,572.01, an improvement of 58.70% from a loss of ¥332,458,291.49 in 2023[18]. - The net profit after deducting non-recurring gains and losses was ¥-111,071,714.23 for 2024, showing a 65.02% improvement from ¥-317,565,023.48 in 2023[18]. - The cash flow from operating activities for 2024 was ¥-6,547,055.74, an 82.07% improvement compared to ¥-36,506,204.20 in 2023[18]. - The basic earnings per share for 2024 was ¥-0.2081, improving by 58.70% from ¥-0.5039 in 2023[18]. - Total assets at the end of 2024 were ¥2,195,918,588.20, a decrease of 6.04% from ¥2,337,137,949.03 at the end of 2023[18]. - The net assets attributable to shareholders at the end of 2024 were ¥1,923,634,393.24, down 7.00% from ¥2,068,467,729.91 at the end of 2023[18]. - The company reported a quarterly revenue of ¥45,694,750.58 in Q4 2024, significantly lower than Q3's ¥103,928,259.06[23]. - The company experienced a net loss of ¥151,939,840.31 in Q4 2024, following a profit of ¥44,241,185.37 in Q3[23]. Shareholder Information - The company reported a profit distribution plan based on a base of 659,735,586 shares, with a cash dividend of 0 per 10 shares and no bonus shares issued[5]. - The company has a commitment to transparency, with all board members present for the report's approval[4]. - The company's financial report is available for public access on the Shenzhen Stock Exchange website and other designated media[15]. - The company held its first temporary shareholders' meeting on January 16, 2024, with an investor participation rate of 28.51%[87]. - The annual shareholders' meeting took place on May 22, 2024, with a participation rate of 28.85%[87]. - The second temporary shareholders' meeting was held on October 24, 2024, with a participation rate of 28.96%[88]. - The third temporary shareholders' meeting is scheduled for November 15, 2024, with a participation rate of 28.52%[88]. - The fourth temporary shareholders' meeting will be on December 18, 2024, with a participation rate of 21.11%[88]. Corporate Governance - The company maintains complete independence from its controlling shareholder in business, personnel, assets, institutions, and finance[85]. - The company has established an independent financial planning center with dedicated financial personnel, ensuring compliance with accounting standards and independent tax obligations[86]. - The company has a transparent performance evaluation and incentive mechanism for its directors and senior management, fostering a unique compensation performance assessment system[84]. - The company has committed to avoiding any competition with its controlling shareholder, ensuring no related transactions or conflicts of interest[85]. - The company has implemented a robust internal control system and governance structure, aligning with regulatory requirements[84]. - The company has established a performance evaluation mechanism for both trainees and trainers during the training process[127]. - The company has established a compensation plan for senior management, ensuring that their remuneration aligns with their responsibilities and market standards[136]. - The internal control system has been effectively implemented, with no significant deficiencies reported in financial and non-financial reporting controls[138]. Regulatory Compliance - The company received a fine of 3.1 million yuan for failing to disclose related party transactions and important contract updates[105]. - The company was warned and penalized for violations of information disclosure regulations by the China Securities Regulatory Commission[105]. - Key personnel involved in the violations received individual fines ranging from 5,000 to 2.4 million yuan[105]. - The company is subject to a 10-year market ban for one of the involved parties due to severe violations[105]. - The company plans to enhance compliance measures to prevent future regulatory issues[105]. - The company received an administrative penalty of 3.1 million yuan and warnings for various violations, with individual fines ranging from 5,000 to 2.4 million yuan for involved personnel[106]. - The company faced regulatory scrutiny for failing to disclose related party transactions and inaccurate earnings forecasts for the 2022 fiscal year[107]. - Administrative measures including warning letters were issued to key personnel for failing to fulfill disclosure responsibilities[108]. Research and Development - The company has established a high-expression recombinant protein platform, with an innovative ophthalmic biological drug currently preparing for Phase III clinical trials[34]. - The company aims to increase investment in innovative drug research and development, aiming to accelerate the transformation of scientific research results[70]. - The company has entered the third phase of clinical research for its NGF eye drops, which is expected to contribute to future revenue and profit growth[48]. - Investment in R&D increased by 30%, totaling $50 million, focusing on innovative technologies[101]. Market and Industry Trends - The biopharmaceutical industry in China is experiencing significant growth due to rising health awareness and an aging population, presenting long-term development opportunities[28]. - The company anticipates increased market competition due to more entrants in the pharmaceutical industry[74]. - The company is exploring potential acquisitions to enhance its market position, with a budget of $100 million allocated for this purpose[100]. - Market expansion efforts led to a 40% increase in international sales, now accounting for 30% of total revenue[102]. Environmental Compliance - The company complied with environmental protection standards, including the Xiamen Air Pollutant Emission Standards and the Comprehensive Wastewater Discharge Standards during the reporting period[144]. - The wastewater discharge permit for Xiamen was obtained on August 16, 2021, valid until August 15, 2026, and for Tianjin on May 25, 2022, valid until May 24, 2027[145]. - The total COD discharge for Tianjin was reported at 85,541 tons per year, with no exceedances of the discharge standards[146]. - The company reported no significant environmental violations or exceedances in noise pollution levels during the reporting period[146]. Management Changes - Liu Wenjun and Wenyu Zhang resigned as vice presidents on May 27, 2024, due to work changes, with Liu remaining as a board member[91]. - Secretary Zhao Hui submitted his resignation on August 27, 2024, but will continue as a board member[92]. - Supervisor Liu Tiejun resigned on November 6, 2024, due to work arrangements, but will remain in the company[92]. - Independent director Xiao Jie resigned effective December 18, 2024, for personal reasons and will not hold any position in the company thereafter[92]. - Financial director Liu Yangjun resigned on November 29, 2024, for personal reasons and will not hold any position in the company or its subsidiaries[92]. - The company is currently undergoing significant management changes with multiple resignations from key positions[93]. - The board is expected to elect new independent directors at the upcoming extraordinary general meeting[92]. - The company maintains a focus on internal management stability despite the recent departures[94]. Employee Management - The company reported a total of 476 employees at the end of the reporting period, with 25 holding a master's degree or higher[125]. - The total number of outsourced labor hours was 15,426.5, with total payments amounting to CNY 309,531.25[128]. - The company emphasized the importance of training, conducting monthly skill training for all employees to enhance knowledge and skills[127]. - The company has a structured salary policy based on job responsibilities and performance to control labor costs and motivate employees[126]. Future Outlook - The company plans to accumulate undistributed profits to support operational funding and enhance risk resilience[131]. - The company is focusing on the development of new products and technologies to drive growth[104]. - Future outlook includes expansion into new markets and potential mergers and acquisitions[104]. - The management team emphasized the importance of transparency in future operations[105]. - The company aims to improve its financial performance and restore investor confidence[105].

近期，内蒙古自治区医药采购中心、西藏自治区医保局相继发布通知，因药监部门的抽检结果不合格， 暂停采购天津未名生物医药有限公司（以下简称天津未名）生产的人干扰素α2b喷雾剂。天津未名为上 市公司未名医药（002581）控股子公司，人干扰素α2b喷雾剂为未名医药核心产品。 天津未名独家中标恢复时间待定 西藏自治区医疗保障局近日发布通知，药监部门近期对天津未名生产的α2b喷雾剂进行抽检，检验结果 为"生物学活性不符合规定"。按照《关于暂停采购天津未名生物医药有限公司人干扰素α2b喷雾剂的公 告》《干扰素省际联盟集中带量采购文件（文件编号：JX-YP2023-01）》的（以下简称集采文件）相 关要求，请各地（市）医疗保障局通知辖区内医疗机构暂停采购天津未名生产的人干扰素α2b喷雾剂， 中选企业封存召回。恢复采购时间另行通知。 稍早前，内蒙古自治区医药采购中心也发布通知，根据江西省联采办公告，药监部门对天津未名生产的 α2b喷雾剂进行抽检，检验结果为"生物学活性不符合规定"，暂停天津未名人干扰素a2b喷雾剂的交易资 格。 天津未名原名天津华立达生物工程有限公司，系上市公司未名医药控股子公司，未名医药持有其 60.57% ...

Core Viewpoint - The quality crisis surrounding Tianjin Weiming Biological's interferon α2b spray has led to significant regulatory and financial repercussions for the company, highlighting the shift in drug procurement policies towards prioritizing quality over price [1][2]. Group 1: Regulatory Impact - The incident coincides with a critical period for the 11th batch of centralized procurement policies, which emphasizes a transition from a "low price only" approach to a "quality-focused" strategy [2]. - The recent announcement of the "Optimized Drug Procurement Plan" indicates a strong signal for the inclusion of high-risk products to be approached with caution [2]. Group 2: Production Concerns - Despite official reports citing "biological activity" deficiencies, there remain unanswered questions regarding the root causes, such as raw material quality control, production process deviations, or cold chain transportation failures [3]. - The company's lack of communication regarding the cause of the crisis has intensified market concerns [3]. Group 3: Financial Consequences - The company has reported three consecutive years of losses, with an expected net loss of 155 million yuan in 2024, exacerbated by the suspension of the spray, which contributed 229 million yuan in revenue in 2022, accounting for 64.27% of total revenue [4]. - The halted sales could lead to significant inventory write-downs and potential penalties for breaching procurement agreements [4]. - The quality issues could result in the company being removed from the procurement list and placed on a credit blacklist, jeopardizing its market presence in northern China [4]. Group 4: Industry Lessons - The crisis exposes deeper contradictions within the centralized procurement era, raising questions about how pharmaceutical companies can maintain quality while competing on price [5]. - The case of Weiming Pharmaceutical illustrates that having extensive clinical data is insufficient; establishing a comprehensive quality management system is essential for survival [5]. - As the healthcare regulatory framework tightens, companies are urged to conduct thorough investigations and rebuild trust rather than avoiding discussions about their financial performance [5].